NetworkNewsBreaks – Pivot Pharmaceuticals Inc. (
Post# of 52
Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning issued a corporate update regarding the progress of its bio-cannabis product pipeline. Per the update, a 1% CBD Oral Micelle Solution developed in Germany is set to market and the company has completed development of two topical creams that employ its patented formulation and delivery systems. Pivot anticipates that it will have numerous products available for sale in Canada on the date legalization officially begins. The company also expects to begin sales in California as of the third quarter 2018, including the launch of its proprietary line of “Ready-to-Infuse-Cannabis” (“RTIC”) natural health products. “Consumers deserve and will demand products that work, whereas regulatory authorities will require high quality, reproducible and safe products. Pivot has positioned itself to be the market leader of bio-cannabis products,” Pivot CEO Dr. Patrick Frankham stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer